Phase 2

Smoking Cessation

Smoking is highly addictive and remains one of the world’s great killers: 6 million per year now and up to 1 billion by the turn of the century. There are 42 million smokers in the US. 70% want to quit, but current products work less than 10% of the time.

Our first product delivers a complete 10-week smoking cessation program. With nicotine replacement therapy timed to smokers’ peak cravings and coordinated digital support tools, we’re providing an integrated collection of clinically validated, personalized interventions to help smokers quit.  


Phase 1b



The United States is in the midst of a prescription opioid epidemic. There are now more than 2 million Americans addicted to prescription opioids and the number of unintentional overdose deaths has more than quadrupled since 1999. Effective solutions are needed, and the time is now. We are developing the world’s first FDA approved treatment to help patients become opioid free, for good.



Optimizing the timing and dosing of Parkinson’s Disease medications is absolutely essential to improving outcomes for patients. We are developing the world’s first solution that delivers the right amount of medication at the right times to minimize off time and dyskinesia, while simultaneously providing patient support and connectivity to caregivers and health care professionals.



Our drug delivery platform can automate the delivery of pain medication to ensure only the correct dosage is taken at the times when patients need it most, keeping pain at bay while minimizing potential addictions. Our solution will also accurately track real-time patient compliance and minimize diversion. Once the pain is gone, the platform can help individuals safely become pain medication free.